RECIST revised: implications for the radiologist. A review article on the modified RECIST guidelineReport as inadecuate




RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline - Download this document for free, or read online. Document in PDF available to download.

European Radiology

, Volume 20, Issue 6, pp 1456–1467

First Online: 22 December 2009Received: 24 July 2009Revised: 03 November 2009Accepted: 06 November 2009

Abstract

The purpose of this review article is to familiarize radiologists with the recently revised Response Evaluation Criteria in Solid Tumours RECIST, used in many anticancer drug trials to assess response and progression rate. The most important modifications are: a reduction in the maximum number of target lesions from ten to five, with a maximum of two per organ, with a longest diameter of at least 10 mm; in lymph nodes LNs the short axis rather than the long axis should be measured, with normal LN measuring <10 mm, non-target LN ≥10 mm but <15 mm and target LN ≥15 mm; osteolytic lesions with a soft tissue component and cystic tumours may serve as target lesions; an additional requirement for progressive disease PD of target lesions is not only a ≥20% increase in the sum of the longest diameter SLD from the nadir but also a ≥5 mm absolute increase in the SLD the other response categories of target lesion are unchanged; PD of non-target lesions can only be applied if the increase in non-target lesions is representative of change in overall tumour burden; detailed imaging guidelines. Alternative response criteria in patients with hepatocellular carcinoma and gastrointestinal stromal tumours are discussed.

KeywordsReview Guidelines Diagnostic imaging Drug evaluation Antitumour drugs RECIST  Download fulltext PDF



Author: Els L. van Persijn van Meerten - Hans Gelderblom - Johan L. Bloem

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents